Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

The discovery of immune checkpoint inhibitors (ICIs) has now been universally
acknowledged as a significant breakthrough in tumor therapy after the targeted treatment of …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …

Strategies to therapeutically target the tumor microenvironment (TME) have emerged as a
promising approach for cancer treatment in recent years due to the critical roles of the TME …

The immune system is the core defense against cancer development and progression.
Failure of the immune system to recognize and eliminate malignant cells plays an important …

In this study, we extended co-indexing of transcriptomes and epitopes (CITE) to the spatial
dimension and demonstrated high-plex protein and whole transcriptome co-mapping. We …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

Myeloid cells are the most abundant immune components of the tumour microenvironment,
where they have a variety of functions, ranging from immunosuppressive to …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …